1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Another Deal Dashed For QLT?

 
• By Lisa LaMotta

Ophthalmology company InSite Vision is opting to take an all-cash bid from an undisclosed bidder than go through with its merger with Canadian biotech QLT – resulting in a second deal that the biotech can't get done.

InSite announced Aug. 21 that its board of directors had determined that the 25 cents per share offer from an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 
• By Andrew McConaghie

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

More from Therapy Areas

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.